Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.54
(0.35%)
CNY 45.54
(0.35%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 427.68 Million | 296.68 Million | 1.07 Billion | 1.24 Billion | 1.15 Billion | 418.03 Million |
| Net Income | 340.06 Million | -439.51 Million | 1.45 Billion | 1.23 Billion | 1.16 Billion | 933.96 Million |
| Depreciation & Amortization | 227.02 Million | 200.34 Million | 184.87 Million | 159.59 Million | 115.83 Million | 91.17 Million |
| Deferred income taxes | -24.28 Million | -143.59 Million | -11.5 Million | -9.05 Million | 20.13 Million | - |
| Stock-based compensation | 50.11 Million | 19.59 Million | - | - | - | - |
| Change in working capital | -373.37 Million | 498.76 Million | -355.54 Million | -134.77 Million | -62.88 Million | -604.21 Million |
| Other non-cash items | 1.13 Billion | 161.09 Million | -203.9 Million | -14.18 Million | -66.29 Million | -2.88 Million |
| Investing Cash Flow | -1.29 Billion | -442.44 Million | -498.13 Million | -3.22 Billion | -1.17 Billion | -690.93 Million |
| Investments in PPE | -553.05 Million | -983.44 Million | -692.08 Million | -582.14 Million | -406.63 Million | -513.44 Million |
| Acquisitions | 355.99 Thousand | 60.42 Thousand | 1.01 Million | 855.97 Thousand | 354.6 Thousand | 12.91 Million |
| Investment purchases | -7.99 Billion | -4.29 Billion | -2.99 Billion | -9.59 Billion | -5.74 Billion | -4.12 Billion |
| Sales/Maturities of investments | 7.25 Billion | 4.8 Billion | 3.22 Billion | 6.96 Billion | 4.94 Billion | 3.98 Billion |
| Other Investing Activities | 1.54 Million | 32.66 Million | -38.47 Million | -6.26 Million | 30.01 Million | -53.45 Million |
| Financing Cash Flow | 754.69 Million | -100.87 Million | -228.93 Million | 2.24 Billion | 3.67 Million | 0.48 |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | -168.46 Million | -224.61 Million | -200.55 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 759.72 Million | 71.36 Million | - | - | - | - |
| Other Financing Activities | 754.69 Million | -3.77 Million | -4.31 Million | 2.44 Billion | - | - |
| Accounts receivables | 480.75 Million | 2.22 Billion | -155.18 Million | -8.71 Million | -87.65 Million | -544.64 Million |
| Accounts payables | -665.1 Million | -1.54 Billion | -30.38 Million | -91.7 Million | 100.22 Million | - |
| Inventory | -239.14 Million | -35.44 Million | -158.46 Million | -25.29 Million | -98.6 Million | -176.01 Million |
| Other working capital | 50.11 Million | -143.59 Million | -11.5 Million | -9.05 Million | 23.14 Million | -428.19 Million |
| Cash at beginning of period | 2.89 Billion | 639.76 Million | 291.33 Million | 33.21 Million | 46.37 Million | 317.31 Million |
| Cash at end of period | 316.48 Million | 397.32 Million | 639.76 Million | 291.33 Million | 33.21 Million | 46.37 Million |
| Capital Expenditure | -553.05 Million | -983.44 Million | -692.08 Million | -582.14 Million | -406.63 Million | -513.44 Million |
| Effect of forex changes on cash | 2.35 Million | 4.19 Million | -2.67 Million | -881.27 Thousand | 4.49 Million | 1.95 Million |
| Net cash flow / Change in cash | -2.57 Billion | -242.43 Million | 348.43 Million | 258.11 Million | -13.15 Million | -270.94 Million |
| Free Cash Flow | -125.36 Million | -686.76 Million | 386.09 Million | 659.19 Million | 747.29 Million | -95.4 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 208.36 Million | 202.89 Million | 96 Million | 73.59 Million | 340.06 Million | 132.32 Million |
| Depreciation & Amortization | - | 62.56 Million | 62.56 Million | 57.41 Million | 227.02 Million | -107.99 Million |
| Deferred income taxes | - | - | - | - | -24.28 Million | -460.95 Million |
| Stock-based compensation | - | 34.54 Million | - | 50.11 Million | 50.11 Million | -23.11 Million |
| Change in working capital | - | -193.81 Million | - | 291.72 Million | -373.37 Million | 344.77 Million |
| Other non-cash items | 155.23 Million | -121.14 Million | 8.05 Million | 212.68 Million | 1.13 Billion | 96.17 Million |
| Investing Cash Flow | -281.64 Million | -203.57 Million | -51.67 Million | -1.09 Billion | -1.29 Billion | 61.54 Million |
| Investments in PPE | -88.45 Million | -69.17 Million | -137.13 Million | -206.24 Million | -553.05 Million | -130.61 Million |
| Acquisitions | - | -1.41 Million | 1.41 Million | 165.99 Thousand | 355.99 Thousand | - |
| Investment purchases | -2.63 Billion | -2.42 Billion | -2.22 Billion | -2.55 Billion | -7.99 Billion | -2.92 Billion |
| Sales/Maturities of investments | 2.43 Billion | 2.29 Billion | 2.3 Billion | 1.63 Billion | 7.25 Billion | 3.11 Billion |
| Other Investing Activities | 462.59 Thousand | 531.78 | 2.02 Million | 33.23 Million | 1.54 Million | -4.29 Million |
| Financing Cash Flow | -34.64 Million | 37.51 Million | -951.94 Thousand | 758.2 Million | 754.69 Million | -1.3 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -16.83 Million | -101.41 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -139.32 Million | 139.32 Million | - | 759.72 Million | 759.72 Million | - |
| Other Financing Activities | -17.81 Million | -100.45 Million | -951.94 Thousand | 3.5 Million | 754.69 Million | -1.3 Million |
| Accounts receivables | - | -124.16 Million | - | 480.75 Million | 480.75 Million | 222.61 Million |
| Accounts payables | - | - | - | - | -665.1 Million | -70.97 Million |
| Inventory | - | -104.19 Million | - | -239.14 Million | -239.14 Million | 122.16 Million |
| Other working capital | - | 34.54 Million | - | 50.11 Million | 50.11 Million | 70.97 Million |
| Cash at beginning of period | 190.78 Million | 2.55 Billion | 316.48 Million | 2.09 Billion | 2.89 Billion | 353.5 Million |
| Cash at end of period | 272.24 Million | 361.99 Million | 2.55 Billion | 316.48 Million | 316.48 Million | 393.5 Million |
| Capital Expenditure | -88.45 Million | -69.17 Million | -137.13 Million | -206.24 Million | -553.05 Million | -130.61 Million |
| Effect of forex changes on cash | -1.35 Million | -262.11 Thousand | 44.44 Thousand | -740.19 Thousand | 2.35 Million | -1.45 Million |
| Net cash flow / Change in cash | 81.45 Million | -2.19 Billion | 2.23 Billion | -1.77 Billion | -2.57 Billion | 40 Million |
| Free Cash Flow | 275.13 Million | -49.98 Million | -33.07 Million | 22.61 Million | -125.36 Million | -149.4 Million |
NPAB
000402
VOIS
300070
JCYCF
POMO3